Second-line lenvatinib in patients with recurrent endometrial cancer.

Ignace Vergote,Matthew A Powell,Michael G Teneriello,David S Miller,Agustin A Garcia,Olga N Mikheeva,Mariusz Bidzinski,Cristina Ligia Cebotaru,Corina E Dutcus,Min Ren,Tadashi Kadowaki,Yasuhiro Funahashi,Richard T Penson

Gynecologic Oncology（2020）

引用 51|浏览89

暂无评分

摘要

Patients with recurrent endometrial cancer treated with second-line lenvatinib experienced modest antitumor activity and treatment was generally well tolerated, with a safety profile consistent with previous studies.

查看译文

关键词

Lenvatinib,Multikinase inhibitor,Endometrial cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要